Loading…
IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking
Although it has long been hypothesized that allergen immunotherapy inhibits allergy, in part, by inducing production of IgG Abs that intercept allergens before they can cross-link mast cell Fc epsilonRI-associated IgE, this blocking Ab hypothesis has never been tested in vivo. In addition, evidence...
Saved in:
Published in: | The Journal of clinical investigation 2006-03, Vol.116 (3), p.833-841 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 841 |
container_issue | 3 |
container_start_page | 833 |
container_title | The Journal of clinical investigation |
container_volume | 116 |
creator | Strait, Richard T Morris, Suzanne C Finkelman, Fred D |
description | Although it has long been hypothesized that allergen immunotherapy inhibits allergy, in part, by inducing production of IgG Abs that intercept allergens before they can cross-link mast cell Fc epsilonRI-associated IgE, this blocking Ab hypothesis has never been tested in vivo. In addition, evidence that IgG-allergen interactions can induce anaphylaxis by activating macrophages through Fc gammaRIII suggested that IgG Ab might not be able to inhibit IgE-mediated anaphylaxis without inducing anaphylaxis through this alternative pathway. We have studied active and passive immunization models in mice to approach these issues and to determine whether any inhibition of anaphylaxis observed was a direct effect of allergen neutralization by IgG Ab or an indirect effect of cross-linking of Fc epsilonRI to the inhibitory IgG receptor Fc gammaRIIb. We demonstrate that IgG Ab produced during the course of an immune response or administered passively can completely suppress IgE-mediated anaphylaxis; that these IgG blocking Abs inhibit IgE-mediated anaphylaxis without inducing Fc gammaRIII-mediated anaphylaxis only when IgG Ab concentration is high and challenge allergen dose is low; that allergen epitope density correlates inversely with the allergen dose required to induce both IgE- and Fc gammaRIII-mediated anaphylaxis; and that both allergen interception and Fc gammaRIIb-dependent inhibition contribute to in vivo blocking Ab activity. |
doi_str_mv | 10.1172/JCI25575 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1378186</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67706011</sourcerecordid><originalsourceid>FETCH-LOGICAL-p295t-794305b873e598ce5e8e1d579db7c0790eefdc64ee2cdb3e4e68637ecdb205ac3</originalsourceid><addsrcrecordid>eNqFkU9LxDAQxXNQXF0FP4Hk5K2aNEnTXgRZ_FMRBNFzSdKxjbZJbbKLXv3kVl1FT56Gmff4zRsGoX1KjiiV6fHVokyFkGIDbROS0qSQLJ-hnRAeCaGcC76FZjTjRS4I20ZvZXOR6M6bJ-sarFy02tcWArautdpGXDZnSQ-1VRHqSVdD-9qpF_thwCu78ji2o182LdY-tp-ABtwkRhgNDNF6Nw1rfG5wo_pe4duy1NiMPoSks-5j6y7afFBdgL11naP787O7xWVyfXNRLk6vkyEtRExkwRkROpcMRJEbEJADrYUsai0NkQUBeKhNxgFSU2sGHLI8YxKmJiVCGTZHJ1_cYamniwy4OKquGkbbq_G18spWfxVn26rxq4oymdOJNUeHa8Don5cQYtXbYKDrlAO_DFUmJckIpf8aU8JzToWYjAe_I_1k-f4PewcFwZK0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20484155</pqid></control><display><type>article</type><title>IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking</title><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Strait, Richard T ; Morris, Suzanne C ; Finkelman, Fred D</creator><creatorcontrib>Strait, Richard T ; Morris, Suzanne C ; Finkelman, Fred D</creatorcontrib><description>Although it has long been hypothesized that allergen immunotherapy inhibits allergy, in part, by inducing production of IgG Abs that intercept allergens before they can cross-link mast cell Fc epsilonRI-associated IgE, this blocking Ab hypothesis has never been tested in vivo. In addition, evidence that IgG-allergen interactions can induce anaphylaxis by activating macrophages through Fc gammaRIII suggested that IgG Ab might not be able to inhibit IgE-mediated anaphylaxis without inducing anaphylaxis through this alternative pathway. We have studied active and passive immunization models in mice to approach these issues and to determine whether any inhibition of anaphylaxis observed was a direct effect of allergen neutralization by IgG Ab or an indirect effect of cross-linking of Fc epsilonRI to the inhibitory IgG receptor Fc gammaRIIb. We demonstrate that IgG Ab produced during the course of an immune response or administered passively can completely suppress IgE-mediated anaphylaxis; that these IgG blocking Abs inhibit IgE-mediated anaphylaxis without inducing Fc gammaRIII-mediated anaphylaxis only when IgG Ab concentration is high and challenge allergen dose is low; that allergen epitope density correlates inversely with the allergen dose required to induce both IgE- and Fc gammaRIII-mediated anaphylaxis; and that both allergen interception and Fc gammaRIIb-dependent inhibition contribute to in vivo blocking Ab activity.</description><identifier>ISSN: 0021-9738</identifier><identifier>DOI: 10.1172/JCI25575</identifier><identifier>PMID: 16498503</identifier><language>eng</language><publisher>United States: American Society for Clinical Investigation</publisher><subject>Anaphylaxis - immunology ; Anaphylaxis - prevention & control ; Animals ; Antibodies, Blocking - physiology ; Antigens - immunology ; Antigens - metabolism ; Cross-Linking Reagents - metabolism ; Immunoglobulin D - metabolism ; Immunoglobulin E - metabolism ; Immunoglobulin E - physiology ; Immunoglobulin G - metabolism ; Immunoglobulin G - pharmacology ; Mast Cells - immunology ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Mice, Knockout ; Receptors, IgG - metabolism</subject><ispartof>The Journal of clinical investigation, 2006-03, Vol.116 (3), p.833-841</ispartof><rights>Copyright © 2006, American Society for Clinical Investigation 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1378186/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1378186/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16498503$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Strait, Richard T</creatorcontrib><creatorcontrib>Morris, Suzanne C</creatorcontrib><creatorcontrib>Finkelman, Fred D</creatorcontrib><title>IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>Although it has long been hypothesized that allergen immunotherapy inhibits allergy, in part, by inducing production of IgG Abs that intercept allergens before they can cross-link mast cell Fc epsilonRI-associated IgE, this blocking Ab hypothesis has never been tested in vivo. In addition, evidence that IgG-allergen interactions can induce anaphylaxis by activating macrophages through Fc gammaRIII suggested that IgG Ab might not be able to inhibit IgE-mediated anaphylaxis without inducing anaphylaxis through this alternative pathway. We have studied active and passive immunization models in mice to approach these issues and to determine whether any inhibition of anaphylaxis observed was a direct effect of allergen neutralization by IgG Ab or an indirect effect of cross-linking of Fc epsilonRI to the inhibitory IgG receptor Fc gammaRIIb. We demonstrate that IgG Ab produced during the course of an immune response or administered passively can completely suppress IgE-mediated anaphylaxis; that these IgG blocking Abs inhibit IgE-mediated anaphylaxis without inducing Fc gammaRIII-mediated anaphylaxis only when IgG Ab concentration is high and challenge allergen dose is low; that allergen epitope density correlates inversely with the allergen dose required to induce both IgE- and Fc gammaRIII-mediated anaphylaxis; and that both allergen interception and Fc gammaRIIb-dependent inhibition contribute to in vivo blocking Ab activity.</description><subject>Anaphylaxis - immunology</subject><subject>Anaphylaxis - prevention & control</subject><subject>Animals</subject><subject>Antibodies, Blocking - physiology</subject><subject>Antigens - immunology</subject><subject>Antigens - metabolism</subject><subject>Cross-Linking Reagents - metabolism</subject><subject>Immunoglobulin D - metabolism</subject><subject>Immunoglobulin E - metabolism</subject><subject>Immunoglobulin E - physiology</subject><subject>Immunoglobulin G - metabolism</subject><subject>Immunoglobulin G - pharmacology</subject><subject>Mast Cells - immunology</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Knockout</subject><subject>Receptors, IgG - metabolism</subject><issn>0021-9738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqFkU9LxDAQxXNQXF0FP4Hk5K2aNEnTXgRZ_FMRBNFzSdKxjbZJbbKLXv3kVl1FT56Gmff4zRsGoX1KjiiV6fHVokyFkGIDbROS0qSQLJ-hnRAeCaGcC76FZjTjRS4I20ZvZXOR6M6bJ-sarFy02tcWArautdpGXDZnSQ-1VRHqSVdD-9qpF_thwCu78ji2o182LdY-tp-ABtwkRhgNDNF6Nw1rfG5wo_pe4duy1NiMPoSks-5j6y7afFBdgL11naP787O7xWVyfXNRLk6vkyEtRExkwRkROpcMRJEbEJADrYUsai0NkQUBeKhNxgFSU2sGHLI8YxKmJiVCGTZHJ1_cYamniwy4OKquGkbbq_G18spWfxVn26rxq4oymdOJNUeHa8Don5cQYtXbYKDrlAO_DFUmJckIpf8aU8JzToWYjAe_I_1k-f4PewcFwZK0</recordid><startdate>20060301</startdate><enddate>20060301</enddate><creator>Strait, Richard T</creator><creator>Morris, Suzanne C</creator><creator>Finkelman, Fred D</creator><general>American Society for Clinical Investigation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20060301</creationdate><title>IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking</title><author>Strait, Richard T ; Morris, Suzanne C ; Finkelman, Fred D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p295t-794305b873e598ce5e8e1d579db7c0790eefdc64ee2cdb3e4e68637ecdb205ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Anaphylaxis - immunology</topic><topic>Anaphylaxis - prevention & control</topic><topic>Animals</topic><topic>Antibodies, Blocking - physiology</topic><topic>Antigens - immunology</topic><topic>Antigens - metabolism</topic><topic>Cross-Linking Reagents - metabolism</topic><topic>Immunoglobulin D - metabolism</topic><topic>Immunoglobulin E - metabolism</topic><topic>Immunoglobulin E - physiology</topic><topic>Immunoglobulin G - metabolism</topic><topic>Immunoglobulin G - pharmacology</topic><topic>Mast Cells - immunology</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Knockout</topic><topic>Receptors, IgG - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Strait, Richard T</creatorcontrib><creatorcontrib>Morris, Suzanne C</creatorcontrib><creatorcontrib>Finkelman, Fred D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Strait, Richard T</au><au>Morris, Suzanne C</au><au>Finkelman, Fred D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>2006-03-01</date><risdate>2006</risdate><volume>116</volume><issue>3</issue><spage>833</spage><epage>841</epage><pages>833-841</pages><issn>0021-9738</issn><abstract>Although it has long been hypothesized that allergen immunotherapy inhibits allergy, in part, by inducing production of IgG Abs that intercept allergens before they can cross-link mast cell Fc epsilonRI-associated IgE, this blocking Ab hypothesis has never been tested in vivo. In addition, evidence that IgG-allergen interactions can induce anaphylaxis by activating macrophages through Fc gammaRIII suggested that IgG Ab might not be able to inhibit IgE-mediated anaphylaxis without inducing anaphylaxis through this alternative pathway. We have studied active and passive immunization models in mice to approach these issues and to determine whether any inhibition of anaphylaxis observed was a direct effect of allergen neutralization by IgG Ab or an indirect effect of cross-linking of Fc epsilonRI to the inhibitory IgG receptor Fc gammaRIIb. We demonstrate that IgG Ab produced during the course of an immune response or administered passively can completely suppress IgE-mediated anaphylaxis; that these IgG blocking Abs inhibit IgE-mediated anaphylaxis without inducing Fc gammaRIII-mediated anaphylaxis only when IgG Ab concentration is high and challenge allergen dose is low; that allergen epitope density correlates inversely with the allergen dose required to induce both IgE- and Fc gammaRIII-mediated anaphylaxis; and that both allergen interception and Fc gammaRIIb-dependent inhibition contribute to in vivo blocking Ab activity.</abstract><cop>United States</cop><pub>American Society for Clinical Investigation</pub><pmid>16498503</pmid><doi>10.1172/JCI25575</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9738 |
ispartof | The Journal of clinical investigation, 2006-03, Vol.116 (3), p.833-841 |
issn | 0021-9738 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1378186 |
source | PubMed Central; EZB Electronic Journals Library |
subjects | Anaphylaxis - immunology Anaphylaxis - prevention & control Animals Antibodies, Blocking - physiology Antigens - immunology Antigens - metabolism Cross-Linking Reagents - metabolism Immunoglobulin D - metabolism Immunoglobulin E - metabolism Immunoglobulin E - physiology Immunoglobulin G - metabolism Immunoglobulin G - pharmacology Mast Cells - immunology Mice Mice, Inbred BALB C Mice, Inbred C57BL Mice, Knockout Receptors, IgG - metabolism |
title | IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A23%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IgG-blocking%20antibodies%20inhibit%20IgE-mediated%20anaphylaxis%20in%20vivo%20through%20both%20antigen%20interception%20and%20Fc%20gamma%20RIIb%20cross-linking&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Strait,%20Richard%20T&rft.date=2006-03-01&rft.volume=116&rft.issue=3&rft.spage=833&rft.epage=841&rft.pages=833-841&rft.issn=0021-9738&rft_id=info:doi/10.1172/JCI25575&rft_dat=%3Cproquest_pubme%3E67706011%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p295t-794305b873e598ce5e8e1d579db7c0790eefdc64ee2cdb3e4e68637ecdb205ac3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20484155&rft_id=info:pmid/16498503&rfr_iscdi=true |